Articles On Impression Healthcare (ASX:IHL)

Incannex Healthcare (ASX: IHL) has received ethics approval for a phase 2b clinical trial to study the therapeutic benefits of its lead drug IHL-42X on patients with obstructive sleep apnoea (OSA). This is the first trial in the company’s a...

In a move that would appear to enthuse the ASX-listed cannabis stocks, the Therapeutic Goods Administration (TGA) has announced an interim decision to reclassify cannabidiol (CBD) products so they can be purchased over the counter at pharma...

Clinical-stage cannabinoid development company Incannex Healthcare (ASX: IHL) has announced positive preliminary results on the anti-inflammatory activity of lead drug IHL-675A against sepsis-associated acute respiratory distress syndrome (...

Cannabinoid development company Incannex Healthcare (ASX: IHL) has commenced a pre-clinical animal trial investigating the neuroprotective capabilities of its lead candidate IHL-216A. The trial will introduce rodents to head trauma, impleme...

From the low in April 2020, the share price has moved up over 138% to where it is today, all this on the back of a rather exciting 12 months for the company. Looking back to August 2019, Impressions Healthcare announced they had officially...

Medicinal cannabis company Incannex Healthcare (ASX:IHL) says mice testing for its cannabidiol treatment has yielded some strong early results. The pre-clinical trial of its IHL-675A treatment was to test its effectiveness against symptoms...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

After reporting amiable progress concerning its sleep apnoea drug IHL-42X just last week, cannabinoid drug development company Incannex Healthcare (ASX: IHL) has published positive results from its animal study into IHL-675A against sepsis-...

Clinical stage cannabinoid development company Incannex Healthcare (ASX: IHL) has partnered with The Alfred Hospital in Melbourne for a Phase 2b dose finding crossover trial investigating the effect of lead candidate IHL-42X on adults diagn...

Money is coming in for marijuana companies, as Bod Australia (ASX:BOD) leads the total today with news of a $2.5m revenue June quarter. That last quarter of the financial year alone accounted for 42 per cent of total revenue booked for the...

Cannabinoid development company Incannex Healthcare (ASX: IHL) has published provisional performance figures for the past quarter, declaring a “record” three months with sales momentum expected to continue going into the next quarter. The c...

Medical cannabis company Impression Healthcare (ASX: IHL) has announced it will discontinue sales of its oral devices by the end of the month to focus its resources exclusively on cannabinoid sales and development activities. The move comes...

Impression Healthcare (ASX: IHL) has begun the first clinical trial to assess the effectiveness of its cannabidiol (CBD) based drug IHL-675A against sepsis associated acute respiratory distress syndrome (SAARDS), the leading cause of death...

Last year was a solid year for many ASX stocks and 2020 was also looking pretty good until COVID-19 struck the markets in late February. Earlier this week Reuben Adams recapped which of last year’s top mining and exploration companies have...

North American pot stocks are roaring back from lows in March but the same cannot be said for their antipodean counterparts, many of which continue to wallow. The New Cannabis Ventures Global Cannabis Stock Index soared 26 per cent last wee...

Medical cannabis company Impression Healthcare (ASX: IHL) has unveiled a high profile acquisition in the form of professional rugby league footballer James Graham. In a statement to the market this morning, Impression announced that Mr Grah...

Impression Healthcare (ASX: IHL) has confirmed in it quarterly report that it has sourced all permits and products required for the start of animal pre-clinical testing of cannabinoid drug IHL-675A developed to treat sepsis-related adult re...

Medical cannabis company Impression Healthcare (ASX: IHL) has confirmed plans to bring its novel cannabinoid formula IHL-216A for patients with traumatic brain injury to the prescription market within the next three years. The company commi...

In many cases COVID-19 causes only mild symptoms. But when it is deadly and requires patients to use ventilators, the most likely culprit is a disease called Acute Respiratory Distress Syndrome (ARDS). Research in US medical journal JAMA In...

Medicinal cannabis company Impression Healthcare (ASX: IHL) has developed a cannabidiol (CBD) based drug that it believes holds potential for the treatment of coronavirus-induced respiratory distress syndrome. The company today unveiled a n...

Medical cannabis company Impression Healthcare (ASX: IHL) has revealed it has received an independent strategic assessment report on the FDA approval pathway for cannabinoid IHL-42X from US-based Camargo Pharmaceuticals. Camargo has advised...

Medical cannabis company Impression Healthcare (ASX: IHL) came out of a trading halt late this morning to unveil an initial order for cannabidiol (CBD) pressurised metered-dose inhalers (similar to an asthma puffer but containing CBD) from...

Australian medical cannabis company Impression Healthcare (ASX: IHL) has taken yet another assertive step towards completing its clinical research program into concussion and traumatic brain injury (TBI) by drafting in former professional A...

Australian medical cannabis company Impression Healthcare (ASX: IHL) has finalised the design of a clinical program to assess novel cannabinoid formula IHL-216A on neurocognitive function after traumatic brain injury and concussion. The for...

There are ASX small caps addressing brain problems and stocks seeking to test cannabis for medicinal purposes and Impression Healthcare (ASX:IHL) is now doing both. This morning the company announced next quarter it would begin a clinical t...

Impression Healthcare (ASX:IHL) is boosting its stock of medicinal cannabis products to “ensure ongoing supply”, as it continues forward with a recent push into the sector. The company has placed a purchase order for 3,000 bottles of cannab...

Medical cannabis company Impression Healthcare (ASX: IHL) has expanded its cannabinoid oil sales program that runs side by side with its extensive base of clinical trial projects. In a statement to the market this morning, Impression announ...

With the health and life science sector being the ASX’s top performer last year, Western Australia is keen to join the party. The state government has formed an Industry Reference Group to come up with a five-year growth plan for the indust...

Impression Healthcare (IHL) has received all permits needed to begin a clinical trial in treating obstructive sleep apnoea The trial will observe daytime drowsiness, cognitive performance and severity of the condition To help manage the...

Medical cannabis company Impression Healthcare (ASX: IHL) is on course to begin a clinical trial using its IHL-42X drug candidate for the treatment of obstructive sleep apnoea. The drug was recently the subject of a patent application that...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Canadians rolled some big… notes last year after handing over $C1 billion ($1.5 billion) or $C24 a person for legal cannabis. Ontario topped the lot, shelling out $C217m on recreational cannabis in the year to September 2019. Regulators in...

Medical cannabis company Impression Healthcare (ASX: IHL) is continuing on its path to developing an effective solution for obstructive sleep apnoea (OSA) having filed a patent application covering IHL-42X in pill form. Impression intends t...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Cannabis has been progressively decriminalised around the world since the early 2000s, starting with Canada granting legal access for medical purposes in 2001 and several other countries following suit. It has taken Australia 15 years to ca...

Cannabis Shares Valuing a cannabis company is becoming an increasingly difficult task. Lately, the cannabis shares have been taking a beat in the domestic markets, falling from their respective all-time highs. The table below provides you w...

Medical cannabis company Impression Healthcare (ASX: IHL) has continued its top-tier recruitment drive with the addition of yet another pharmaceutical industry expert into its ranks. Former Roche (mkt cap: US$256B) executive John Michailidi...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

In the few short years since cannabis companies first floated on stock exchanges around the world, they have developed a reputation for being volatile and high risk. At the start, stocks exploded in value, peaking around the start of 2018....

Dr Sud Agarwal presented at Impression Healthcare’s (ASX: IHL) annual general meeting on Friday 4th October 2019 to discuss Incannex’s portfolio. Under the guidance of Impression’s new medical advisory board, IHL has commenced the full drug...

Impression Healthcare Limited (ASX: IHL) has filed a patent application covering IHL-216A. IHL-216A to be used as neuroprotective agent to cure Traumatic Brain Injury (TBI). TBI accounts for ~10 million deaths/hospitalisation annually in...

Impression Healthcare (ASX: IHL) has opted to file a patent application for a neuroprotective agent that could potentially aid people that suffer concussions – a growing issue in contact sports such as boxing, American and Australian-rules...

Despite the Australian government approving the use of cannabis for medical purposes close to three years ago, there is still some red tape in the way of Australians getting access to the drug. A lot of the information out there can be vagu...

Following a busy few months on the recruitment and brand licensing fronts, Impression Healthcare (ASX: IHL) has appointed an additional duo of leading medical experts to its Medical Advisory Board, overseen by medicinal cannabis expert Dr S...

THC Global (ASX:THC) has secured 18 hectares of agricultural land and 6.6 hectares of existing hydroponic greenhouses as it prepares to deliver medicinal cannabis products to Australian patients by early next year. The land will be turned i...

Impression Healthcare (ASX: IHL) has bolstered its Medical Advisory Board by appointing two leading medical experts possessing extensive expertise within two key market niches currently being explored by the company – namely, traumatic brai...

Impression Healthcare (ASX: IHL) has added further weight to its broad-based position within the medical industry by signing a product supply agreement with Air Liquide Healthcare Australia, a subsidiary of Air Liquide S.A. for an initial p...

The legalisation of medical cannabis in southeast Asia is gathering steam with news that Thailand has officially started distributing cannabis oil to eligible patients over the past week. Advocates hope that the move is a sign of things to...

Australia has a well-regulated and high-quality health sector, while its medical research and healthcare infrastructure is of world class. Over the years, the health and medical industry in the country has grown at a rapid pace in terms of...

Following last week’s deal that saw Impression Healthcare (ASX: IHL) secure the cannabinoid materials it needs to conduct a series of clinical trials, the cannabis company has announced that it has successfully registered its second clinica...